1010120-60-1

Basic information

• Product Name: ethyl {[(5-bromopyridin-2-yl)amino]carbonothioyl}-carbamate
• Synonyms: ethyl {[(5-bromopyridin-2-yl)amino]carbonothioyl}-carbamate;N-[[(5-Bromo-2-pyridinyl)amino]thioxomethyl]-carbamic acid ethyl este;ethyl (5-bromopyridin-2-yl)carbamothioylcarbamate
• CAS NO: 1010120-60-1
• Molecular Formula: C₉H₁₀BrN₃O₂S
• Molecular Weight: 304
• Mol File: 1010120-60-1.mol
• Article Data: 28

Chemical Properties

• Appearance: /
• Density: 1.643±0.06 g/cm3(Predicted)
• PKA: 6.19±0.70(Predicted)
• CAS DataBase Reference: ethyl {[(5-bromopyridin-2-yl)amino]carbonothioyl}-carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl {[(5-bromopyridin-2-yl)amino]carbonothioyl}-carbamate(1010120-60-1)
• EPA Substance Registry System: ethyl {[(5-bromopyridin-2-yl)amino]carbonothioyl}-carbamate(1010120-60-1)

Safety Data

• Hazardous Substances Data: 1010120-60-1(Hazardous Substances Data)

Upstream product

• 1072-97-5 5-bromo-2-pyridylamine 
• 16182-04-0 Ethoxycarbonyl isothiocyanate 

Downstream Products

• 1443764-16-6 tert-butyl {4-[2-({4-[(3-fluoroazetidin-1-yl)carbonyl]-2-(2,2,2-trifluoroethoxy)phenyl}amino)[1,2,4]triazolo[1,5-α]pyridin-6-yl]phenyl}carbamate 
• 1443764-04-2 tert-butyl [4-(2-{[4-(dimethylcarbamoyl)-2-methoxyphenyl]amino}[1,2,4]triazolo[1,5-a]pyridin-6-yl)phenyl]carbamate 
• 1443764-03-1 3-(4-{[6-(4-aminophenyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino}-3-methoxyphenyl)-1,3-oxazolidin-2-one 
• 1443764-01-9 (4-{[6-(4-aminophenyl)[1 ,2,4]triazolo[1,5-α]pyridin-2-yl]amino}-3-methoxyphenyl)(azetidin-1-yl)methanone 
• 1443764-00-8 tert-butyl [4-(2-{[4-(azetidin-1-ylcarbonyl)-2-methoxyphenyl]amino}-[1,2,4]triazolo[1,5-α]pyridin-6-yl)phenyl]carbamate 
• 1443763-99-2 (4-{[6-(4-aminophenyl)[1,2,4]triazolo[1,5-α]pyridin-2-yl]amino}-3-methoxyphenyl)(3-fluoroazetidin-1-yl)methanone 
• 1443763-98-1 tert-butyl {4-[2-({4-[(3-fluoroazetidin-1-yl)carbonyl]-2-methoxyphenyl}amino)[1,2,4]triazolo[1,5-α]pyridin-6-yl]phenyl}carbamate 
• 1443763-91-4 6-(4-aminophenyl)-N-[4-(methylsulfonyl)-2-(2,2,2-trifluoroethoxy)phenyl][1,2,4]triazolo[1,5-α]pyridin-2-amine 
• 1443763-90-3 tert-butyl [4-(2-{[4-(methylsulfonyl)-2-(2,2,2-trifluoroethoxy)phenyl]amino}[1,2,4]triazolo[1,5-α]pyridin-6-yl)phenyl]carbamate 
• 1443763-89-0 6-(4-aminophenyl)-N-[2-methoxy-4-(methylsulfonyl)phenyl][1,2,4]triazolo[1,5-α]pyridin-2-amine 
• 1443763-88-9 tert-butyl [4-(2-{[2-methoxy-4-(methylsulfonyl)phenyl]amino}[1,2,4]-triazolo[1,5-α]pyridin-6-yl)phenyl]carbamate 
• 1443763-70-9 (-)-2-(4-fluorophenyl)-3-hydroxy-N-[4-(2-{[4-(methylsulfonyl)-2-(2,2,2-trifluoroethoxy)phenyl]amino}[1,2,4]triazolo[1,5-a]pyridin-6-yl)phenyl] propanamide 
• 1443763-68-5 (2R)-2-(4-fluorophenyl)-N-[4-(2-{[2-methoxy-4-(2-oxo-1,3-oxazolidin-3-yl)-phenyl]amino}[1,2,4]triazolo[1,5-a]pyridin-6-yl)phenyl]propanamide 
• 1443763-67-4 (2R)-N-[4-(2-{[4-(azetidin-1-ylcarbonyl)-2-methoxyphenyl]amino}[1,2,4]-triazolo[1,5-α]pyridin-6-yl)phenyl]-2-(4-fluorophenyl)propanamide 

Relevant articles and documents

Design, synthesis, and evaluation of potent RIPK1 inhibitors with in vivo anti-inflammatory activity

RIPK1 plays a key role in the necroptosis pathway that regulates inflammatory signaling and cell death in various diseases, including inflammatory and neurodegenerative diseases. Herein, we report a series of potent RIPK1 inhibitors, represented by compound 70. Compound 70 efficiently blocks necroptosis induced by TNFα in both human and mouse cells (EC50 = 17–30 nM). Biophysical assay demonstrates that compound 70 potently binds to RIPK1 (Kd = 9.2 nM), but not RIPK3 (Kd > 10,000 nM). Importantly, compound 70 exhibits greatly improved metabolic stability in human and rat liver microsomes compared to compound 6 (PK68), a RIPK1 inhibitor reported in our previous work. In addition, compound 70 displays high permeability in Caco-2 cells and excellent in vitro safety profiles in hERG and CYP assays. Moreover, pre-treatment of 70 significantly ameliorates hypothermia and lethal shock in SIRS mice model. Lastly, compound 70 possesses favorable pharmacokinetic parameters with moderate clearance and good oral bioavailability in SD rat. Taken together, our work supports 70 as a potent RIPK1 inhibitor and highlights its potential as a prototypical lead for further development in necroptosis-associated inflammatory disorders.

METHOD FOR PREPARING SUBSTITUTED TRIAZOLOPYRIDINES

The present invention relates to methods of preparing substituted triazolopyridine compounds of general formula (I) as described and defined herein, as well as to intermediate compounds useful in the preparation of said compounds.

COMBINATIONS FOR THE TREATMENT OF CANCER

The present invention relates to combinations of at least two compounds A and B, compound A being an inhibitor of Mps-1 kinase, and compound B being an inhibitor of an anti-apoptotic protein of the Bcl-2 family. Another aspect of the present invention relates to the use of such combinations as described supra for the preparation of a medicament for the treatment or prophylaxis of a disease, particularly for the treatment of cancer. Another aspect of the present invention relates to the use of an anti- apoptotic protein from the Bcl-2 family as a sensitizer of cells to Mps-1 inhibitors. Another aspect of the present invention relates to the use of the ratio of pro-apoptotic and anti-apoptotic proteins from the Bcl-2 family in a biological sample as a biomarker for a Mps-1 kinase inhibitor treatment.